Salud financiera de hoja de balance de Cue Biopharma
Salud financiera controles de criterios 5/6
Cue Biopharma tiene un patrimonio de los accionistas total de $30.0M y una deuda total de $7.2M, lo que sitúa su ratio deuda-patrimonio en 24%. Sus activos y pasivos totales son $54.0M y $23.9M respectivamente.
Información clave
24.0%
Ratio deuda-patrimonio
US$7.21m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$41.03m |
| Patrimonio | US$30.04m |
| Total pasivo | US$23.91m |
| Activos totales | US$53.95m |
Actualizaciones recientes sobre salud financiera
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money
Apr 16
Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?
Dec 30Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?
Aug 11Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt
Sep 23Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
May 12We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth
Nov 04Recent updates
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money
Apr 16Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?
Dec 30Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?
Aug 11Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug
Oct 04Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt
Sep 23News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat
Aug 26Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates
Aug 10Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%
May 18Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
May 12Cue Biopharma: A First Assessment
May 11Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Mar 19Cue Biopharma: Too Long To Arrive At Topline Trial Data
Feb 23We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth
Nov 04Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer
Jun 10Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth
Jun 07Cue Biopharma's CUE-101 shows encouraging action in HPV+ head and neck cancer patients
May 10How Many Cue Biopharma, Inc. (NASDAQ:CUE) Shares Did Insiders Buy, In The Last Year?
Mar 21We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Feb 22Is Cue Biopharma, Inc. (NASDAQ:CUE) Popular Amongst Insiders?
Jan 27
Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022
Jan 07Reflecting on Cue Biopharma's (NASDAQ:CUE) Share Price Returns Over The Last Year
Dec 25Independent Director Aaron Fletcher Just Bought 3.9% More Shares In Cue Biopharma, Inc. (NASDAQ:CUE)
Nov 29We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Nov 24Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($44.7M) de CUE superan a sus pasivos a corto plazo ($18.1M).
Pasivo a largo plazo: Los activos a corto plazo de CUE ($44.7M) superan a sus pasivos a largo plazo ($5.8M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: CUE tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de CUE ha crecido de 0% a 24% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: CUE tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: CUE dispone de suficiente cash runway para 1 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 9.6% cada año.